<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3860">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04668339</url>
  </required_header>
  <id_info>
    <org_study_id>ARCT-021-04</org_study_id>
    <nct_id>NCT04668339</nct_id>
  </id_info>
  <brief_title>A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults</brief_title>
  <official_title>A Phase 2 Randomized, Observer-Blind, Placebo-Controlled Study to Assess the Safety, Reactogenicity, and Immunogenicity of the SARS CoV-2 Vaccine ARCT-021 in Healthy Adult Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arcturus Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arcturus Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, randomized, placebo-controlled, and observer-blind study in healthy&#xD;
      adults.&#xD;
&#xD;
      The study will evaluate the safety, tolerability, and immunogenicity of the SARS-CoV-2 RNA&#xD;
      vaccine candidate against COVID-19:&#xD;
&#xD;
      As 2 doses (at two different dose levels), separated by 28 days or as 1 dose&#xD;
&#xD;
      In adults 18 years of age and older&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multiregional, multicenter, Phase 2, randomized, observer-blind study designed to&#xD;
      evaluate the safety, reactogenicity, and immunogenicity of the study vaccine in younger and&#xD;
      older adult participants. Enrolled participants will be randomly assigned to receive either&#xD;
      study vaccine ARCT-021 or placebo (sterile saline).&#xD;
&#xD;
      Approximately 600 participants (300 each in younger [18 to &lt;56 years of age in United States&#xD;
      or 21 to &lt;56 years of age in Singapore] and older [≥56 years of age] participants) will be&#xD;
      enrolled (including at least 50% of participants in the older cohort ≥65 years of age).&#xD;
      Participants will be stratified by age and then randomly assigned (3 ARCT-021:1 placebo) to&#xD;
      receive 2 doses of study vaccine separated by 28 days. At 180 days after second study&#xD;
      vaccination (Day 208), participants in Study Groups 1, 2, and 3 will be randomly assigned&#xD;
      again to receive a single booster dose of study vaccine (randomly assigned as 1 ARCT-021:1&#xD;
      placebo). Study Group 4 will not be randomized but will receive 1 dose of placebo at Day 208.&#xD;
      Study Groups are summarized in Table 1. Study vaccine will be administered in an&#xD;
      observer-blind fashion. Participants will be followed for safety and immunogenicity through&#xD;
      180 days after booster vaccination (Day 388). At a subset of clinical sites, all enrolled&#xD;
      participants will also undergo blood sampling for evaluation of CMI responses.&#xD;
&#xD;
      Vaccine doses will be assigned as follows:&#xD;
&#xD;
      Younger Age Cohort:&#xD;
&#xD;
      Study Group 1: n= 75 participants, ARCT-021 7.5 µg (first dose), Placebo (second dose Study&#xD;
      Group 2: n= 75 participants, ARCT-021 5.0 µg (first dose), 5.0 µg (second dose) Study Group&#xD;
      3: n= 75 participants, ARCT-021 7.5 µg (first dose), 7.5 µg (second dose) Study Group 4: n=&#xD;
      75 participants, Placebo (first dose), Placebo (second dose)&#xD;
&#xD;
      Booster Vaccine:&#xD;
&#xD;
      Study Groups 1, 2, 3: 113 participants, ARCT-021 5.0 µg or 7.5 µg, 112 participants, Placebo&#xD;
      Study Group 4: n= 75 participants, Placebo&#xD;
&#xD;
      Older Age Cohort:&#xD;
&#xD;
      Study Group 1: n= 75 participants, ARCT-021 7.5 µg (first dose), Placebo (second dose Study&#xD;
      Group 2: n= 75 participants, ARCT-021 5.0 µg (first dose), 5.0 µg (second dose) Study Group&#xD;
      3: n= 75 participants, ARCT-021 7.5 µg (first dose), 7.5 µg (second dose) Study Group 4: n=&#xD;
      75 participants, Placebo (first dose), Placebo (second dose)&#xD;
&#xD;
      Booster Vaccine:&#xD;
&#xD;
      Study Groups 1, 2, 3: 113 participants, ARCT-021 5.0 µg or 7.5 µg, 112 participants, Placebo&#xD;
      Study Group 4: n= 75 participants, Placebo&#xD;
&#xD;
      A DSMB will be in place to independently review the safety data of participants. Pausing&#xD;
      Rules are also utilized in this study to reduce risk to study participants.&#xD;
&#xD;
      The expected duration of participation for an individual participant is approximately 14&#xD;
      months, inclusive of the Screening period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 7, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>sequential assignment</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Observer blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentages of participants reporting solicited local adverse events</measure>
    <time_frame>for 7 days following each dose administration</time_frame>
    <description>Adverse events reported daily in a diary that reflect common symptoms or findings at the injection site following vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentages of participants reporting solicited systemic adverse events</measure>
    <time_frame>for 7 days following each dose administration</time_frame>
    <description>Adverse events reported daily in a diary that reflect generalized symptoms following vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentages of participants reporting adverse events</measure>
    <time_frame>28 days following each dose administration</time_frame>
    <description>spontaneously reported adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentages of participants reporting serious adverse events</measure>
    <time_frame>Day 0 to Day 388</time_frame>
    <description>unsolicited adverse events that meet the definition of serious</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentages of participants reporting medically attended adverse events</measure>
    <time_frame>Day 0 to Day 388</time_frame>
    <description>unsolicited adverse events that lead to healthcare provider visit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentages of participants reporting new onset of chronic disease</measure>
    <time_frame>Day 0 to Day 388</time_frame>
    <description>unsolicited adverse events associated with new diagnosis of chronic disease</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentages of participants with abnormal chemistry and hematology values</measure>
    <time_frame>Day 0 to Day 215</time_frame>
    <description>chemistry and hematology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SARS-CoV-2 serum neutralizing antibody levels, expressed as GMTs</measure>
    <time_frame>Day 0 to Day 388</time_frame>
    <description>neutralizing antibody response</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in SARS-CoV-2 serum neutralizing titers from before vaccination to each subsequent time point, expressed as GMFRs</measure>
    <time_frame>Through Day 388</time_frame>
    <description>neutralizing antibody response</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentages of participants achieving greater than or equal to 2-fold and 4-fold rises from before vaccination in SARS-CoV-2 serum neutralizing antibody levels</measure>
    <time_frame>Through Day 388</time_frame>
    <description>neutralizing antibody response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SARS-CoV-2 anti-S1, anti-RBD, and anti-N binding antibody levels, expressed as GMCs</measure>
    <time_frame>Day 0 to Day 388</time_frame>
    <description>SARS-CoV-2 anti S1, RBD, N binding antibody responses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in SARS-CoV-2 anti-S1, anti-RBD, and anti-N binding antibody levels from before vaccination to each subsequent time point, expressed as GMFRs</measure>
    <time_frame>Through Day 388</time_frame>
    <description>SARS-CoV-2 anti S1, RBD, N binding antibody responses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of participants achieving greater than or equal to 2-fold and 4-fold rises from before vaccination in SARS-CoV-2 SARS-CoV-2 anti-S1, anti-RBD, and anti-N binding antibody levels</measure>
    <time_frame>Through Day 388</time_frame>
    <description>SARS-CoV-2 anti S1, RBD, N binding antibody responses</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Covid19</condition>
  <condition>SARS-CoV Infection</condition>
  <condition>Corona Virus Infection</condition>
  <arm_group>
    <arm_group_label>Study Group 1, Younger Adult Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive one dose of ARCT-021 on Day 0, one dose of Placebo (saline) on Day 28 and on Day 208 either one dose of ARCT-021 or one dose of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Group 2, Younger Adult Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive one dose of ARCT-021 on Day 0, a second dose of ARCT-021 on Day 28 and on Day 208 either one dose of ARCT-021 or one dose of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Group 3, Younger Adult Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive one dose of ARCT-021 on Day 0, a second dose of ARCT-021 on Day 28 and on Day 208 either one dose of ARCT-021 or one dose of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Group 4, Younger Adult Participants</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive one of Placebo (Saline) on Day 0, one dose of Placebo on Day 28, and one dose of Placebo on Day 208</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Group 1, Older Adult Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive one dose of ARCT-021 on Day 0, one dose of Placebo (saline) on Day 28 and on Day 208 either one dose of ARCT-021 or one dose of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Group 2, Older Adult Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive one dose of ARCT-021 on Day 0, a second dose of ARCT-021 on Day 28 and on Day 208 either one dose of ARCT-021 or one dose of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Group 3, Older Adult Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive one dose of ARCT-021 on Day 0, a second dose of ARCT-021 on Day 28 and on Day 208 either one dose of ARCT-021 or one dose of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Group 4, Older Adult Participants</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive one dose of Placebo (saline) on Day 0, a second dose of Placebo on Day 28 and a third dose of Placebo on Day 208</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ARCT-021 single dose priming</intervention_name>
    <description>ARCT-021 higher dose (one dose) + placebo (one dose)</description>
    <arm_group_label>Study Group 1, Older Adult Participants</arm_group_label>
    <arm_group_label>Study Group 1, Younger Adult Participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ARCT-021 two lower dose priming</intervention_name>
    <description>ARCT-021 lower dose (two doses, Day 0 and Day 28)</description>
    <arm_group_label>Study Group 2, Older Adult Participants</arm_group_label>
    <arm_group_label>Study Group 2, Younger Adult Participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ARCT-021 two higher dose priming</intervention_name>
    <description>ARCT-021 higher dose (two doses, Day 0 and Day 28)</description>
    <arm_group_label>Study Group 3, Older Adult Participants</arm_group_label>
    <arm_group_label>Study Group 3, Younger Adult Participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo (two doses), priming</intervention_name>
    <description>Placebo (two doses, Day 0 and Day 28)</description>
    <arm_group_label>Study Group 4, Older Adult Participants</arm_group_label>
    <arm_group_label>Study Group 4, Younger Adult Participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Randomized booster</intervention_name>
    <description>ARCT-021 (single dose) OR placebo, booster</description>
    <arm_group_label>Study Group 1, Older Adult Participants</arm_group_label>
    <arm_group_label>Study Group 1, Younger Adult Participants</arm_group_label>
    <arm_group_label>Study Group 2, Older Adult Participants</arm_group_label>
    <arm_group_label>Study Group 2, Younger Adult Participants</arm_group_label>
    <arm_group_label>Study Group 3, Older Adult Participants</arm_group_label>
    <arm_group_label>Study Group 3, Younger Adult Participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo booster</intervention_name>
    <description>Placebo (single dose)</description>
    <arm_group_label>Study Group 4, Older Adult Participants</arm_group_label>
    <arm_group_label>Study Group 4, Younger Adult Participants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Individuals who:&#xD;
&#xD;
          1. are able to provide consent&#xD;
&#xD;
          2. agree to comply with all study visits and procedures&#xD;
&#xD;
          3. are willing and able to adhere to study restrictions&#xD;
&#xD;
          4. are sexually active and willing to adhere to contraceptive requirements&#xD;
&#xD;
          5. are male or female ≥18 or (in Singapore) ≥21 years of age&#xD;
&#xD;
          6. are medically stable&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Individuals who:&#xD;
&#xD;
          1. have had SARS-CoV-2 infection or COVID-19 disease.&#xD;
&#xD;
          2. have had cancer except for cancers that were treated and that have low risk of&#xD;
             returning&#xD;
&#xD;
          3. have chronic kidney disease&#xD;
&#xD;
          4. have some chronic lung diseases&#xD;
&#xD;
          5. have some heart conditions&#xD;
&#xD;
          6. have compromised immune systems&#xD;
&#xD;
          7. are obese&#xD;
&#xD;
          8. have sickle cell disease or some other blood disorders&#xD;
&#xD;
          9. are current smokers and/or use illegal drugs&#xD;
&#xD;
         10. have Type 2 diabetics&#xD;
&#xD;
         11. are immunocompromised, immunodeficient or have had a transplant&#xD;
&#xD;
         12. have autoimmune disease&#xD;
&#xD;
         13. have other severe or uncontrolled diseases or disease that may interfere with the&#xD;
             interpretation of the study&#xD;
&#xD;
         14. have a positive test for hepatitis B or C or human immunodeficiency virus&#xD;
&#xD;
         15. have had a severe reaction to previous investigational vaccines&#xD;
&#xD;
         16. have a fever or are feeling sick close to the time of the first vaccination of the&#xD;
             study&#xD;
&#xD;
         17. have positive drug test at screening&#xD;
&#xD;
         18. are pregnant&#xD;
&#xD;
         19. are breastfeeding&#xD;
&#xD;
         20. have a bleeding disorder&#xD;
&#xD;
         21. have previously received an investigational coronavirus vaccine (SARS-CoV(1) or MERS)&#xD;
             or who plan to be in other COVID-19 studies&#xD;
&#xD;
         22. have recently been vaccinated with other vaccines&#xD;
&#xD;
         23. have recently received blood products&#xD;
&#xD;
         24. who work at one of the clinic sites participating in this study, work at Arcturus, who&#xD;
             work at other companies that monitor the study or close family members to the sites,&#xD;
             Arcturus, or partners involved in study monitoring&#xD;
&#xD;
         25. other restrictions may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Arcturus Therapeutics</last_name>
    <phone>(858) 900-2660</phone>
    <email>clinicaltrials@arcturusrx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arcturus Investigational Site 103</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>480-782-5552</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcturus Investigational Site 107</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85741</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>520-333-4515</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcturus Investigational Site 112</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>619-291-2845</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcturus Investigational Site 104</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32934</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>321-259-3880</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcturus Investigational Site 105</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>407-426-9299</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcturus Investigational Site 106</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>727-544-6367</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcturus Investigational Site 109</name>
      <address>
        <city>The Villages</city>
        <state>Florida</state>
        <zip>32162</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>352-261-0901</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcturus Investigational Site 101</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>309-672-1910</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcturus Investigational Site 110</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>301-309-8610</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcturus Investigational Site 102</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>864-305-1411</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcturus Investigational Site 111</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>512-201-8032</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcturus Investigational Site 108</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>972-241-1222</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcturus Investigational Site 201</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+65 6323 7532</phone>
    </contact>
  </location>
  <location_countries>
    <country>Singapore</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 25, 2020</study_first_submitted>
  <study_first_submitted_qc>December 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2020</study_first_posted>
  <last_update_submitted>January 10, 2021</last_update_submitted>
  <last_update_submitted_qc>January 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV-2 Vaccine</keyword>
  <keyword>Coronavirus Virus Diseases</keyword>
  <keyword>RNA COVID 19</keyword>
  <keyword>COVID 19 Vaccine Arcturus</keyword>
  <keyword>self amplifying RNA vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data will only be made available to study investigators at this time.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

